evaluate novo nordisk on glp-1 agonists Free Comparison Chart: and GIP/GLP-1 Receptor for Type 2 Diabetes 🔗 Link in bio #FOAMed #Type2Diabetes #GLP1 Frontiers | Clinical perspectives on

Each serving delivers 100mg of S-Acetyl-L-Glutathione, giving you a consistent dose in every capsule

The top dose produced 20.9% average weight loss over 72 weeks and 20.2% in a direct comparison with semaglutides 13.7%. Its second receptor, GIP, separates tirzepatide from approved single-receptor GLP-1 drugs and helps explain the larger population-level weight loss. That 20.9% came from participants averaging about 105 kg at a BMI of 38, most of whom were sedentary

Raising the caloric floor by 200-300 calories daily, particularly from protein sources, supports the metabolic environment needed for tissue preservation

Jorsal A, Kistorp C, Holmager P, Tougaard RS, Nielsen R, Hnselmann A, et al

a consensus report by the American Diabetes Asso-ciation (ADA) and the European Association for the Study of Diabetes (EASD)